Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 2
2010 2
2011 1
2013 5
2014 1
2016 2
2017 1
2018 1
2020 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.
Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, Maurier F, Jouneau S, Bienvenu B, Puéchal X, Aumaître O, Le Guenno G, Le Quellec A, Cevallos R, Fain O, Godeau B, Seror R, Dunogué B, Mahr A, Guilpain P, Cohen P, Aouba A, Mouthon L, Guillevin L; French Vasculitis Study Group. Comarmond C, et al. Arthritis Rheum. 2013 Jan;65(1):270-81. doi: 10.1002/art.37721. Arthritis Rheum. 2013. PMID: 23044708 Free article.
This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes. METHODS: A retrospective study of EGPA patients in the French Vasculitis Study Group cohort who satisfied the American College of Rheumatology criteria a …
This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes. METHODS: A re …
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Delestre F, Charles P, Karras A, Pagnoux C, Néel A, Cohen P, Aumaître O, Faguer S, Gobert P, Maurier F, Samson M, Godmer P, Bonnotte B, Cottin V, Hanrotel-Saliou C, Le Gallou T, Carron PL, Desmurs-Clavel H, Direz G, Jourde-Chiche N, Lifermann F, Martin-Silva N, Pugnet G, Quéméneur T, Matignon M, Benhamou Y, Daugas E, Lazaro E, Limal N, Ducret M, Huart A, Viallard JF, Hachulla E, Perrodeau E, Puechal X, Guillevin L, Porcher R, Terrier B; French Vasculitis Study Group (FVSG). Delestre F, et al. Ann Rheum Dis. 2024 Jan 11;83(2):233-241. doi: 10.1136/ard-2023-224623. Ann Rheum Dis. 2024. PMID: 37918894
OBJECTIVE: To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tailored RTX and 36-month RTX in preventing relapses in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who achie …
OBJECTIVE: To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tail …
Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.
Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A. Lidove O, et al. Genet Med. 2010 Nov;12(11):668-79. doi: 10.1097/GIM.0b013e3181f13b75. Genet Med. 2010. PMID: 20962662 Free article. Review.
Incidence of antibodies against agalsidase alfa and agalsidase beta observed during major clinical studies suggests a greater antigenic response to agalsidase beta. Further studies are required to confirm the long-term clinical benefits of enzyme replacement therapy. More …
Incidence of antibodies against agalsidase alfa and agalsidase beta observed during major clinical studies suggests a greater antigenic resp …
Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
Hughes DA, Aguiar P, Lidove O, Nicholls K, Nowak A, Thomas M, Torra R, Vujkovac B, West ML, Feriozzi S. Hughes DA, et al. Among authors: lidove o. Orphanet J Rare Dis. 2022 Feb 8;17(1):42. doi: 10.1186/s13023-022-02181-4. Orphanet J Rare Dis. 2022. PMID: 35135579 Free PMC article.
BACKGROUND: Variable disease progression confounds accurate prognosis in Fabry disease. Evidence supports the long-term benefit of early intervention with disease-specific therapy, but current guidelines recommend treatment initiation based on signs that may present too la …
BACKGROUND: Variable disease progression confounds accurate prognosis in Fabry disease. Evidence supports the long-term benefit of ea …
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B, Pagnoux C, Perrodeau É, Karras A, Khouatra C, Aumaître O, Cohen P, Decaux O, Desmurs-Clavel H, Maurier F, Gobert P, Quémeneur T, Blanchard-Delaunay C, Bonnotte B, Carron PL, Daugas E, Ducret M, Godmer P, Hamidou M, Lidove O, Limal N, Puéchal X, Mouthon L, Ravaud P, Guillevin L; French Vasculitis Study Group. Terrier B, et al. Among authors: lidove o. Ann Rheum Dis. 2018 Aug;77(8):1150-1156. doi: 10.1136/annrheumdis-2017-212768. Epub 2018 May 3. Ann Rheum Dis. 2018. PMID: 29724729 Clinical Trial.
OBJECTIVE: To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides. ...
OBJECTIVE: To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutroph …
The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature.
Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F. Bekri S, et al. Among authors: lidove o. Cardiovasc Hematol Agents Med Chem. 2006 Oct;4(4):289-97. doi: 10.2174/187152506778520718. Cardiovasc Hematol Agents Med Chem. 2006. PMID: 17073606 Review.
The recent introduction of a specific treatment for Fabry disease in the form of enzyme replacement therapy (ERT) has led to the need for a biological marker, in place of a clinical sign, for evaluating the efficacy of treatment and also as a tool for following the long term …
The recent introduction of a specific treatment for Fabry disease in the form of enzyme replacement therapy (ERT) has led to the need for a …
Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature.
Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T. Lidove O, et al. Int J Clin Pract. 2007 Feb;61(2):293-302. doi: 10.1111/j.1742-1241.2006.01237.x. Int J Clin Pract. 2007. PMID: 17263716 Review.
Further prospective studies are required to confirm the long-term clinical benefits of ERT. More studies are also needed on the effects of ERT in women and on the use of ERT early in the course of Fabry disease, to prevent organ damage. ...
Further prospective studies are required to confirm the long-term clinical benefits of ERT. More studies are also needed on the effec …
[Clinical efficacy of enzyme replacement therapy in Fabry disease. A critical review].
Lidove O, Papo T. Lidove O, et al. Rev Med Interne. 2009 Oct;30(10):920-9. doi: 10.1016/j.revmed.2009.04.003. Epub 2009 Jun 12. Rev Med Interne. 2009. PMID: 19524334 Review. French.
Further prospective studies are required to confirm the long term clinical benefits of ERT. More specific studies are also needed in women or with ERT earlier in the course of Fabry disease to assess prevention of organ damage....
Further prospective studies are required to confirm the long term clinical benefits of ERT. More specific studies are also needed in …
Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients.
Rohmer J, Couteau-Chardon A, Trichereau J, Panel K, Gesquiere C, Ben Abdelali R, Bidet A, Bladé JS, Cayuela JM, Cony-Makhoul P, Cottin V, Delabesse E, Ebbo M, Fain O, Flandrin P, Galicier L, Godon C, Grardel N, Guffroy A, Hamidou M, Hunault M, Lengline E, Lhomme F, Lhermitte L, Machelart I, Mauvieux L, Mohr C, Mozicconacci MJ, Naguib D, Nicolini FE, Rey J, Rousselot P, Tavitian S, Terriou L, Lefèvre G, Preudhomme C, Kahn JE, Groh M; CEREO and GBMHM collaborators. Rohmer J, et al. Am J Hematol. 2020 Nov;95(11):1314-1323. doi: 10.1002/ajh.25945. Epub 2020 Sep 19. Am J Hematol. 2020. PMID: 32720700 Free article. Clinical Trial.
Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis.
Puéchal X, Pagnoux C, Perrodeau É, Hamidou M, Boffa JJ, Kyndt X, Lifermann F, Papo T, Merrien D, Smail A, Delaval P, Hanrotel-Saliou C, Imbert B, Khouatra C, Lambert M, Leské C, Ly KH, Pertuiset E, Roblot P, Ruivard M, Subra JF, Viallard JF, Terrier B, Cohen P, Mouthon L, Le Jeunne C, Ravaud P, Guillevin L; French Vasculitis Study Group. Puéchal X, et al. Arthritis Rheumatol. 2016 Mar;68(3):690-701. doi: 10.1002/art.39450. Arthritis Rheumatol. 2016. PMID: 26473755 Free article. Clinical Trial.
OBJECTIVE: Findings from the WEGENT trial and other short-term studies have suggested that azathioprine (AZA) or methotrexate (MTX) could effectively maintain remission of granulomatosis with polyangiitis (Wegener's) (GPA) or microscopic polyangiitis (MPA). This study was …
OBJECTIVE: Findings from the WEGENT trial and other short-term studies have suggested that azathioprine (AZA) or methotrexate (MTX) c …
18 results